Non-small cell lung cancer, pleural effusion and carcinomatosis: always a criterion of inoperability?

Yablonskii, Piotr; Nefedov, Andrey; Арсеньев, Андрей; Kozak, Andrey; Mortada, Makhmud; Patsyuk, Alexey

doi:10.21037/amj.2020.02.07

Cited by 6 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All consecutive patients who were diagnosed histologically as NSCLC between January 1, 2012 and December 31, 2017 were reviewed. NSCLC patients with suspected MPE were included if they met the following criteria: unilateral pleural effusion on the same side of lung cancer [ 10 ] ; age ≥18 years; no cardiomegaly; and no chronic kidney disease and not receiving renal replacement therapy. The exclusion criteria were as follows: patients with minimal pleural effusion, which is defined as a depth of pleural effusion <10 mm measured perpendicular to the parietal pleura on axial computed tomography (CT) [ 11 , 12 ] ; patients who refused anticancer treatment including the management of MPE; or patients who died within 3 months from initial diagnosis.…”

Section: Methodsmentioning

confidence: 99%

Clinical course of asymptomatic malignant pleural effusion in non-small cell lung cancer patients

et al. 2021

View full text Add to dashboard Cite

The British Thoracic Society guidelines recommend observation for patients with asymptomatic malignant pleural effusion (MPE). However, asymptomatic MPE can become symptomatic. This study examined the clinical course of asymptomatic MPE in patients with non-small cell lung cancer (NSCLC), including the incidence and timing of symptom development of asymptomatic MPE and the associated factors. Retrospective data of 4822 NSCLC patients between January 2012 and December 2017 were reviewed. Symptom development of asymptomatic MPE was defined as the development of symptoms requiring additional treatment, such as insertion of a chest tube, within 1 year in patients who lacked MPE symptoms at the time of diagnosis. Clinical information, pathological parameters, and radiological characteristics were reviewed. Patient data up to 1 year from the initial diagnosis were reviewed. Of 113 patients with asymptomatic MPE, 46 (41%) became symptomatic within 1 year despite appropriate anticancer treatment. The median time to symptom development was 4 months, and 38 patients (83%) developed symptoms within 6 months. Multivariate logistic regression showed that female sex (odds ratio [OR], 0.256; 95% confidence interval [CI], 0.101–0.649; P = .004) and the depth of pleural effusion on initial computed tomography (CT) (OR, 0.957; 95% CI, 0.932–0.982; P = .001) were independently associated with symptom development of asymptomatic MPE. A fraction of 41% of patients with asymptomatic MPE became symptomatic within 1 year. Female sex and larger MPE on initial CT were independently associated with symptom development of asymptomatic MPE.

show abstract

Section: Methodsmentioning

confidence: 99%

Clinical course of asymptomatic malignant pleural effusion in non-small cell lung cancer patients

et al. 2021

View full text Add to dashboard Cite

show abstract

“…6 Geneplus-Beijing, Beijing, China. 7 Department of Oncology and Hematology, Xiamen Haicang Hospital, Xiamen 361026, Fujian, China.…”

Section: Abbreviationsmentioning

confidence: 99%

“…Peritoneal metastasis appears to be a common pattern and is associated with a poorer prognosis than other sites in gastric (GC) and colorectal cancers (CRC) [5,6]. The pleura is also a common metastatic site in lung cancer and worsens the survival rate [7]. Ascites (ASC) and PE are usually available in large quantities, and can be extracted using minimally invasive procedures in patients with peritoneal and pleural involvement.…”

Section: Introductionmentioning

confidence: 99%

Liquid biopsy using ascitic fluid and pleural effusion supernatants for genomic profiling in gastrointestinal and lung cancers

Yang

et al. 2022

BMC Cancer

View full text Add to dashboard Cite

Background Precision medicine highlights the importance of incorporating molecular genetic testing into standard clinical care. Next-generation sequencing can detect cancer-specific gene mutations, and molecular-targeted drugs can be designed to be effective for one or more specific gene mutations. For patients with special site metastases, it is particularly important to use appropriate samples for genetic profiling. This study aimed to determine whether genomic profiling using ASC and PE is effective in detecting genetic mutations. Methods Tissues, plasma, ascites (ASC) supernatants, and pleural effusion (PE) samples from gastrointestinal cancer patients with peritoneal metastasis and lung cancer patients with pleural metastasis were collected for comprehensive genomic profiling. The samples were subjected to next-generation sequencing using a panel of 59 or 1021 cancer-relevant genes panel. Results A total of 156 tissues, 188 plasma samples, 45 ASC supernatants, and 1 PE samples from 304 gastrointestinal cancer patients and 446 PE supernatants, 122 tissues, 389 plasma samples, and 45 PE sediments from 407 lung cancer patients were analyzed. The MSAF was significantly higher in ASC and PE supernatant than that in plasma ctDNA (50.00% vs. 3.00%, p < 0.0001 and 28.5% vs. 1.30%, p < 0.0001, respectively). The ASC supernatant had a higher actionable mutation rate and more actionable alterations than the plasma ctDNA in 26 paired samples. The PE supernatant had a higher total actionable mutation rate than plasma (80.3% vs. 48.4%, p < 0.05). The PE supernatant had a higher frequency of uncommon variations than the plasma regardless of distant organ metastasis. Conclusion ASC and PE supernatants could be better alternative samples when tumor tissues are not available, especially in patients with only peritoneal or pleural metastases.

show abstract

“…Peritoneal metastasis appears to be the common pattern and is associated with a poor prognosis than other sites in gastric and colorectal cancer [5, 6]. Pleura is also the common metastasis site in lung cancer and worsen the survival [7]. Ascites (ASC) and pleura effusion (PE) were usually available in large quantities, by minimally invasive procedures, in patients with peritoneal and pleura involvement.…”

mentioning

confidence: 99%

Liquid Biopsy Using Ascites and Pleural Effusion Supernatant for Genomic Profiling in Gastrointestinal and Lung Cancers

Yang

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Precision medicine highlights the importance of incorporating molecular genetic testing into standard clinical care. Next-generation sequencing (NGS) can detect cancer-specific gene mutations, and molecular targeted drugs can be designed to be effective for one or more specific gene mutations. For patients with special site metastasis, it is particularly important to use appropriate samples for genetic profiling test.Methods: Tissues, plasma, ascites (ASC) supernatants, pleural effusion (PE) samples from gastrointestinal (GI) patients with peritoneal metastasis and lung cancer patients with pleural metastasis were collected for comprehensive genomic profiling. The sample were performed on next-generation sequencing (NGS) using 59 or 1021 cancer-relevant genes panel. Results: The study enrolled 156 tissues, 188 plasma, 45 ascites supernatants, and 1 pleural effusion in 304 GI group and 446 pleural effusion supernatants, 122 tissues, 389 plasma, 45 pleural effusion sediments in 407 lung cancer group. The MSAF were significantly higher in ASC and PE supernatant than plasma ctDNA (50.18% ± 32.03% vs 12.31% ± 19.90%, p < 0.0001 and 33.74% ± 28.34% vs 6.28% ± 12.17%, p < 0.0001, respectively). ASC supernatant had a higher actionable mutation rate than plasma. ASC supernatant accounts for more actionable alterations than plasma ctDNA in 26 paired samples. PE supernatant had higher total actionable mutation rate than plasma (80.3% vs 48.4%, p < 0.05). PE supernatant had a higher frequency of uncommon variations than plasma no matter had distant organ metastasis. Conclusion: ASC and PE supernatants could be better alternatives when tumor tissues are not available in the real world, especially in patients who have only peritoneal or pleural metastases.

show abstract

Non-small cell lung cancer, pleural effusion and carcinomatosis: always a criterion of inoperability?

Cited by 6 publications

References 0 publications

Clinical course of asymptomatic malignant pleural effusion in non-small cell lung cancer patients

Clinical course of asymptomatic malignant pleural effusion in non-small cell lung cancer patients

Liquid biopsy using ascitic fluid and pleural effusion supernatants for genomic profiling in gastrointestinal and lung cancers

Liquid Biopsy Using Ascites and Pleural Effusion Supernatant for Genomic Profiling in Gastrointestinal and Lung Cancers

Contact Info

Product

Resources

About